Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer

Objective. The M. D. Anderson Symptom Inventory (MDASI) captures the severity of common cancer symptoms from the patient's perspective. We describe the validity and sensitivity of a module of the MDASI to be used with patients having ovarian cancer (MDASI-OC). Methods. Ovarian cancer-specific module items were developed from 14 qualitative patient interviews. 128 patients with invasive epithelial ovarian, peritoneal, or fallopian-tube cancer treated at The University of Texas MD Anderson Cancer Center were recruited. Patients completed the MDASI-OC, socio-demographic questionnaires, the Functional Assessment of Cancer Therapy-Ovary (FACT-O), and a global quality-of-life (QOL) item. Reliability was assessed using Cronbach alpha, and sensitivity using a known group was assessed. Construct validity was tested using exploratory factor analysis. Results. The sample was primarily white (85.2%), had a mean age of 57.5 years (+/- 12.7 years), and had previously been treated with chemotherapy (75.0%) and/or surgery (93.8%). Approximately 30% of patients reported disturbed sleep, fatigue, or numbness/tingling of at least moderate severity (>= 5 on a 0-10 scale). On the ovarian-cancer-specific symptoms, approximately 20% reported back pain, feeling bloated, or constipation of at least moderate severity. Factor analysis revealed six underlying constructs (pain/sleep; cognitive; disease-related and numbness; treatment-related; affective; gastrointestinal-specific). MDASI-OC symptom and interference items had Cronbach alpha values of 0.90 and 0.89, respectively. The MDASI-OC was sensitive to symptom severity by performance status (p = 0.009), QOL (p = 0.002), and FACT-O scores (p < 0.001). Conclusions. The 27-item MDASI-OC meets common criteria for validation and reliability and is sensitive to expected changes in symptoms related to differences in disease and treatment status. (C) 2013 Elsevier Inc. All rights reserved.